Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022
Rhea-AI Summary
Vir Biotechnology, Inc. (Nasdaq: VIR) will provide a corporate update and report its financial results for Q4 and full year 2021 on February 24, 2022. The update will include insights into the company’s performance and is expected to be accessible on its website post-market close. Vir specializes in immunology, focusing on serious infectious diseases, using four technology platforms designed to enhance the immune system. Its pipeline includes candidates targeting COVID-19 and other infectious diseases.
Positive
- Plans to report financial results for Q4 and full year 2021 on February 24, 2022.
- Focus on serious infectious diseases with a diverse pipeline targeting COVID-19 and more.
Negative
- None.
News Market Reaction – VIR
In the trading session that priced this news, VIR declined 0.71%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2021, on Thursday, February 24, 2022.
The update will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio.
About Vir Biotechnology
Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus. Vir routinely posts information that may be important to investors on its website.
